Clinicopathological markers associated with recurrence in ductal carcinoma in situ of breast by age group

Abstract

In the present study, factors related to the recurrence of breast ductal carcinoma in situ (DCIS) in Korean patients were identified, and the prognostic factors for each age group were explored. Methods: The subjects were 226 patients who were diagnosed with DCIS by histopathologic examination, and the effect of representative prognostic factors that are known already, including estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) status, Ki-67 levels, and adjuvant therapy on the recurrence of DCIS was analyzed by using the Cox proportional hazard model. Results: Among the 226 subjects, 11 patients underwent the recurrence of breast cancer. The average follow-up period was 52.7 ±23.5 months. The average age of the subjects was 50.6±9.3 years. Among the DCIS patients, the recurrence of breast cancer was significantly higher in the ER negative patients and those who have a Ki-67 level over 20%. However, the PR and HER2 status did not significantly affect breast cancer recurrence. The result also showed that only ER negative was a significant factor before the age of 50 years and that only the Ki-67 level over 20% was a significant factor to the patients 50 years of age or older. Conclusion: DCIS patients should be appropriately treated and managed depending on their age and clinicopathological factors to prevent the recurrence of DCIS.

Clinicopatholgic Characteristics to the Relapse on Ductal Carcinoma <i>In Situ</i>: Ki-67 Index as the Most Influential Prognostic Factor

“…Retrospective studies comparing clinical and pathological factors with DCIS recurrence showed various results according to their clinical setting. Choi et al [15] reported that age and ER status were associated with recurrence in DCIS and Williams et al [16] suggested that molecular phenotypes such as, luminal A, luminal B, HER2 type, and triple negative, and high Ki-67 expression was a significant predictor of invasive recurrence. Yun et al [17] reviewed 431 patients with DCIS who received BCS to evaluate recurrence pattern after treatment.…”